Optimisation of glycemic control with empagliflozin/linagliptin combination in a patient with type 2 diabetes mellitus uncontrolled on multiple glucose-lowering drugs and reluctant to initiate insulin

Data has demonstrated the efficiency of utilizing a combination of empagliflozin and linagliptin to effectively manage glycemic levels in patients with Type 2 diabetes (T2D) who are uncontrolled on metformin. In this retrospective analysis, we examine the combination of empagliflozin and linagliptin added to existing combination of multiple glucose-lowering medications sans insulin, which revealed significant improvements in both glycemic and cardio-renal outcomes for adults with T2D. This combination therapy was well-tolerated and showed promising clinical effectiveness when used in combination with commonly prescribed antidiabetic drugs for patients with inadequately controlled diabetes.

Sponsored as an educational program by Boehringer Ingelheim Singapore Pte. Ltd.